The Provera mediation is intended to combat hormone-dependent forms of recurrent breast cancer, recurrent and/or metastatic cancer of the endometrium, kidney.
The Provera dosage is prescribed by the doctor individually. The drug is intended for oral intake. Tablets should be taken during or immediately after a meal, without chewing, drinking plenty of water. If necessary, tablets can be crushed.
• Breast cancer in postmenopausal women: 400-1500 mg/day.
• Endometrial cancer and kidney cancer: 100-600 mg/day.
• Metastatic prostate cancer: 100-500 mg/day.
• Anorexia and cachexia syndrome: 1000 mg/day.
• Indications for use
• The Provera pill is used in the following diagnoses:
• cancer cachexia;
• metastatic kidney cancer (except for cancer of the renal pelvis);
• breast cancer;
• endometrial cancer;
• prostate cancer.
Contraindications:
• Hypersensitivity and intolerance to the components of the drug;
• period of pregnancy and lactation;
• tumors of the genital organs or the mammary gland (except in cases of anticancer therapy);
• bleeding of the genital tract for unclear reasons;
• thrombophlebitis, thromboembolism or stroke (increased risk of development or history);
• liver failure;
• hypercalcemia;
• epilepsy;
• a migraine;
• bronchial asthma;
• heart or kidney failure;
• diabetes;
• depressive states.
Provera Side Effects
When using tablets, the following undesirable effects are possible:
• feeling of depression and sleeplessness;
• dizziness and headache;
• feeling sleepy;
• asthenia;
• abdominal pain;
• the occurrence of discomfort in the epigastrium;
• thrombophlebitis;
• irritability;
• thromboembolism;
• cerebrovascular disorders;
• renal thrombosis;
• insomnia;
• allergic rash and urticaria;
• anaphylaxis;
• hyperthermia;
• alopecia;
• a headache;
• acne and weight loss
• cervical erosion;
• increased nipple sensitivity;
• vaginal discharge (spotting, bloody);
• agalactorrhea;
• impaired glucose tolerance;
• hirsutism;
• moon face;
Overdose may increase the symptoms described above
Reviews
There are no reviews yet.